念珠菌病治疗市场－全球产业规模、份额、趋势、机会和预测，按给药途径、药物类型、解剖类型、最终用户、地区和竞争细分，2020 年至 2030 年

2024 年全球念珠菌病治疗市场价值为 33.2 亿美元，预计到 2030 年将达到 47.8 亿美元，预测期内的复合年增长率为 6.22%。念珠菌病是一种主要由念珠菌引起的真菌感染，仍然是所有年龄层日益严重的医疗保健问题。念珠菌病的表现形式包括口腔鹅口疮、阴道感染、食道念珠菌病和侵袭性念珠菌病，它会对免疫功能低下人群（包括 HIV 感染者/爱滋病患者、癌症患者和器官移植接受者）带来更大的风险。抗生素的广泛使用（有时是不恰当的）进一步导致了念珠菌患者病率的上升。因此，全球治疗市场对有效抗真菌治疗的需求不断增长。随着患者群体的多样化和不断扩大，对创新和有针对性的治疗的需求继续推动市场的投资和进步。

关键市场驱动因素

念珠菌病发生率上升

主要市场挑战

抗真菌抗药性

主要市场趋势

抗真菌药物研发与创新

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球念珠菌病治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依给药途径（注射、软膏、口服）
  • 依药物类型（多烯类、唑类、棘白菌素类、其他）
  • 依解剖学类型（口腔念珠菌病、外阴阴道念珠菌病、皮肤念珠菌病、侵袭性念珠菌病、系统性念珠菌病）
  • 按最终用户（医院和诊所、零售药局、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美念珠菌病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲念珠菌病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太念珠菌病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲念珠菌病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲念珠菌病治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球念珠菌病治疗市场：SWOT 分析

第 14 章：竞争格局

• Bruker Corporation
• Astellas Pharma Inc.
• SCYNEXIS, Inc.
• NovaDigm Therapeutics
• Mycovia Pharmaceuticals, Inc.
• Cidara Therapeutics Inc.
• Pfizer Inc.
• Bayer AG
• Viatris Inc.

第 14 章：10 Novabiotics 有限公司

第 15 章：策略建议

第16章调查会社について・免责事项

The Global Candidiasis Therapeutics Market was valued at USD 3.32 billion in 2024 and is projected to reach USD 4.78 billion by 2030, registering a CAGR of 6.22% during the forecast period. Candidiasis, a fungal infection primarily caused by Candida species, remains a growing healthcare concern across all age groups. Manifesting in forms such as oral thrush, vaginal infections, esophageal candidiasis, and invasive candidiasis, it poses heightened risks for immunocompromised populations-including individuals with HIV/AIDS, cancer patients, and transplant recipients. The widespread and sometimes inappropriate use of antibiotics has further contributed to its rising prevalence. In response, the global therapeutics market is witnessing rising demand for effective antifungal treatments. With a diverse and expanding patient base, the need for innovative and targeted therapies continues to drive investment and advancements within the market.

Key Market Drivers

The Rising Incidence of Candidiasis

Candidiasis, primarily caused by Candida albicans and increasingly by drug-resistant species such as Candida auris, is on the rise globally. In 2024, the CDC reported more than 34,000 cases of candidemia in the United States alone, underscoring a significant year-over-year increase. The emergence of Candida auris, detected in over 40 countries, highlights the infection's expanding global impact. Key contributing factors include the widespread use of antibiotics, which disrupt healthy microbial balance, and a growing population of immunocompromised individuals-such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. Aging demographics further heighten vulnerability to these infections. As the disease burden escalates, pharmaceutical and biotechnology companies are intensifying R&D efforts to develop advanced antifungal drugs. This momentum is reinforced by the need for therapeutics that are both more effective and capable of overcoming resistance, with many new treatments currently progressing through clinical trials.

Key Market Challenges

Antifungal Resistance

Antifungal resistance poses a major obstacle to candidiasis treatment worldwide. The increasing prevalence of multidrug-resistant strains, particularly Candida auris, has complicated the clinical landscape. In 2023 alone, over 2,400 cases of Candida auris were reported in the United States-nearly doubling from 2020 figures. Resistance to key antifungal classes such as azoles and echinocandins limits treatment options and increases reliance on less effective or more toxic alternatives. This trend is especially concerning in high-risk populations, including immunocompromised patients, where timely and successful intervention is crucial. The challenge underscores the need for continuous innovation and investment in resistance-mitigating therapies.

Key Market Trends

Antifungal Drug Development and Innovation

A leading trend in the Candidiasis Therapeutics Market is the sustained focus on novel antifungal drug development. The rise in drug-resistant infections has prompted pharmaceutical firms to prioritize research targeting resistant Candida species. Innovations include the development of next-generation antifungal agents as well as the exploration of combination therapies, which utilize multiple antifungal drugs to improve efficacy and reduce resistance risk. These advancements reflect a broader movement toward personalized, more effective treatment options, ensuring better outcomes for patients with complex or persistent infections.

Key Market Players

• Basilea Pharmaceutica Ltd
• Astellas Pharma Inc.
• SCYNEXIS, Inc.
• NovaDigm Therapeutics
• Mycovia Pharmaceuticals, Inc.
• Cidara Therapeutics Inc.
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Novabiotics Limited

Report Scope:

In this report, the Global Candidiasis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Candidiasis Therapeutics Market, By Route of Administration:

• Injection
• Ointment
• Oral

Candidiasis Therapeutics Market, By Drug Type:

• Polyene
• Azole
• Echinocandin
• Other

Candidiasis Therapeutics Market, By Anatomy Type:

• Oral Candidiasis
• Vulvovaginal Candidiasis
• Cutaneous Candidiasis
• Invasive Candidiasis
• Systemic Candidiasis

Candidiasis Therapeutics Market, By End-User:

• Hospitals and Clinics
• Retail Pharmacies
• Other

Candidiasis Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Candidiasis Therapeutics Market.

Available Customizations:

Global Candidiasis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Candidiasis Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Injection, Ointment, Oral)
  • 5.2.2. By Drug Type (Polyene, Azole, Echinocandin, Other)
  • 5.2.3. By Anatomy Type (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis)
  • 5.2.4. By End-User (Hospitals and Clinics, Retail Pharmacies, Other)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Candidiasis Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Drug Type
  • 6.2.3. By Anatomy Type
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Candidiasis Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Anatomy Type
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Candidiasis Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Anatomy Type
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Candidiasis Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Anatomy Type
      • 6.3.3.2.4. By End-User

7. Europe Candidiasis Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Drug Type
  • 7.2.3. By Anatomy Type
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Candidiasis Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Anatomy Type
      • 7.3.1.2.4. By End-User
  • 7.3.2. United Kingdom Candidiasis Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Anatomy Type
      • 7.3.2.2.4. By End-User
  • 7.3.3. Italy Candidiasis Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Anatomy Type
      • 7.3.3.2.4. By End-User
  • 7.3.4. France Candidiasis Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Drug Type
      • 7.3.4.2.3. By Anatomy Type
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Candidiasis Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Drug Type
      • 7.3.5.2.3. By Anatomy Type
      • 7.3.5.2.4. By End-User

8. Asia-Pacific Candidiasis Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Drug Type
  • 8.2.3. By Anatomy Type
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Candidiasis Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Anatomy Type
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Candidiasis Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Anatomy Type
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Candidiasis Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Anatomy Type
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Candidiasis Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Drug Type
      • 8.3.4.2.3. By Anatomy Type
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Candidiasis Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Drug Type
      • 8.3.5.2.3. By Anatomy Type
      • 8.3.5.2.4. By End-User

9. South America Candidiasis Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Drug Type
  • 9.2.3. By Anatomy Type
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Candidiasis Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Anatomy Type
      • 9.3.1.2.4. By End-User
  • 9.3.2. Argentina Candidiasis Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Anatomy Type
      • 9.3.2.2.4. By End-User
  • 9.3.3. Colombia Candidiasis Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Anatomy Type
      • 9.3.3.2.4. By End-User

10. Middle East and Africa Candidiasis Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Drug Type
  • 10.2.3. By Anatomy Type
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Candidiasis Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Drug Type
      • 10.3.1.2.3. By Anatomy Type
      • 10.3.1.2.4. By End-User
  • 10.3.2. Saudi Arabia Candidiasis Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Drug Type
      • 10.3.2.2.3. By Anatomy Type
      • 10.3.2.2.4. By End-User
  • 10.3.3. UAE Candidiasis Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Drug Type
      • 10.3.3.2.3. By Anatomy Type
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Candidiasis Therapeutics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Bruker Corporation
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Astellas Pharma Inc.
• 14.3. SCYNEXIS, Inc.
• 14.4. NovaDigm Therapeutics
• 14.5. Mycovia Pharmaceuticals, Inc.
• 14.6. Cidara Therapeutics Inc.
• 14.7. Pfizer Inc.
• 14.8. Bayer AG
• 14.9. Viatris Inc.

14.10 Novabiotics Limited

15. Strategic Recommendations

16.About Us & Disclaimer